COMPASS THERAPEUTICS, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
COMPASS THERAPEUTICS, INC. (CMPX) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$7.16 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Income Statement
us-gaap:ProfitLoss · last filed 2022-05-09
- COMPASS THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-03-31 was -$7.16M.
- COMPASS THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-12-31 was -$12.98M.
- COMPASS THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-09-30 was -$5.98M.
- COMPASS THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-06-30 was -$55.80M.
- COMPASS THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$82.18M.
- COMPASS THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$29.50M.
- COMPASS THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2019 was -$34.74M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$7.16M 10-Q · filed 2022-05-09 | -$20.14M derived: sum of 2 quarters · filed 2022-05-09 | -$26.12M derived: sum of 3 quarters · filed 2022-05-09 | -$81.92M derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-12-31 | -$12.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$18.96M derived: sum of 2 quarters · filed 2022-03-18 | -$74.76M derived: sum of 3 quarters · filed 2022-03-18 | -$82.18M 10-K · filed 2022-03-18 |
| 2021-09-30 | -$5.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$61.78M derived: sum of 2 quarters · filed 2021-11-12 | -$69.20M 10-Q · filed 2021-11-12 | -$77.59M derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-06-30 | -$55.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$63.22M 10-Q · filed 2021-08-16 | -$71.61M derived: sum of 3 quarters · filed 2022-05-09 | -$80.76M derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-03-31 | -$7.42M 10-Q · filed 2022-05-09 | -$15.81M derived: sum of 2 quarters · filed 2022-05-09 | -$24.96M derived: sum of 3 quarters · filed 2022-05-09 | -$30.52M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$8.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$17.54M derived: sum of 2 quarters · filed 2022-03-18 | -$23.10M derived: sum of 3 quarters · filed 2022-03-18 | -$29.50M 10-K · filed 2022-03-18 |
| 2020-09-30 | -$9.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$14.71M derived: sum of 2 quarters · filed 2021-11-12 | -$21.11M 10-Q · filed 2021-11-12 | -$27.72M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$5.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$11.96M 10-Q · filed 2021-08-16 | -$18.57M derived: sum of 3 quarters · filed 2021-08-16 | -$27.12M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | -$6.40M 10-Q · filed 2021-04-30 | -$13.01M derived: sum of 2 quarters · filed 2021-04-30 | -$21.57M derived: sum of 3 quarters · filed 2021-04-30 | |
| 2019-12-31 | -$6.61M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | -$15.16M derived: sum of 2 quarters · filed 2021-03-05 | -$34.74M 10-K · filed 2021-03-05 | |
| 2019-09-30 | -$8.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$28.13M 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | -$19.58M 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |